TRIFLUPERIDOL: A BUTYROPHENONE DERIVATIVE
Abstract
Under double-blind conditions, the effects of trifluperidol, one of the butyrophenone derivatives, were contrasted with the effects of chlorpromazine in each of 2 groups of 18 chronic schizophrenics who had received no medications for at least 60 days. Trifluperidol had a significantly greater therapeutic effect than chlorpromazine not only in the global ratings of improvement but in the majority of the objective psychologic tests as well. Correlation between these clinical measurements was excellent. During the past 4 years of double-blind studies on our drug research ward, trifluperidol is the only experimental drug that has surpassed chlorpromazine in therapeutic efficacy.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
